Innoviva Inc (INVA)

$23.57 +0.09 (0.38%)
Market Cap 1.74B
Revenue (ttm) 411.33M
Net Income (ttm) 271.17M
EPS (ttm) N/A
PE Ratio 5.82
Forward PE 11.81
Profit Margin 65.93%
Debt to Equity Ratio 0.22
Volume 456,500
Avg Vol 741,032
Day's Range N/A - N/A
Shares Out 74.07M
Stochastic %K 39%
Beta 0.40
Analysts Sell
Price Target $33.20

Company Profile

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 238 9600
Address:
1350 Old Bayshore Highway, Suite 400, Burlingame, United States
All4Retiring
All4Retiring Apr. 20 at 11:21 PM
$INVA $ARMP Innoviva (through its subsidiary Innoviva Strategic Opportunities LLC) beneficially owns approximately 55.47 million shares of Armata Pharmaceuticals (ARMP) on a fully diluted/as-converted and as-exercised basis, representing about 83.1–83.3% of Armata’s common stock. http://stocktitan.net This includes: • Direct/common shares owned: 25,076,769 shares (roughly 68–69% of currently outstanding shares). http://wallstreetzen.com • Additional shares from warrants (about 10.65 million) and a convertible loan (about 19.74 million shares upon conversion, excluding accrued interest). http://sec.gov Armata has approximately 36.2–36.6 million shares outstanding as of early 2026 (e.g., ~36.23 million in recent reports and ~36.6 million as of March 2026). http://finance.yahoo.com This ownership stems from multiple investments since 2020 (initial ~$25M deal, followed by $45M in 2022, and later credit facilities/loans that are partially convertible), with Innoviva as Armata’s largest/majority shareholder
0 · Reply
wizeinvesting
wizeinvesting Apr. 16 at 8:30 AM
$INVA $CCJ $NBR $WEN While most investors remain focused on large-cap leaders and headline-driven trades, a quieter shift is unfolding beneath the surface. Small-cap stocks—long overlooked due to higher rates and macro uncertainty—are beginning to present selective opportunities where price no longer reflects underlying business performance. The key isn’t simply that these stocks are cheap, but that some are still executing, generating earnings, and adapting despite negative sentiment. From a profitable biotech with royalty-backed income, to an energy services firm leveraged to global demand, to a consumer brand priced for decline, the real opportunity lies in identifying where pessimism has gone too far. In the final section, we break down why the biggest edge in this market isn’t finding the cheapest stocks—but understanding which discounted companies are still fundamentally intact, and how that distinction can define... https://www.wizeinvesting.com/p/how-ccj-delivered-607-gains-in-5-years
0 · Reply
Doozio
Doozio Apr. 14 at 12:37 AM
$INVA it’s about to get obvious ONTO 🐒🍌🧠⏰♾️?
0 · Reply
stubbybrown
stubbybrown Apr. 10 at 2:37 AM
$INVA Innoviva, Inc. has the greatest future revenue growth potential in the Innoviva Specialty Therapeutics (IST) segment, specifically within hospital-based critical care and infectious disease treatments. The IST division is experiencing rapid growth, with net product sales rising by 77% in 2025 to $172.1 million and projected to exceed $150 million in U.S. sales in 2026. Key Products in High-Need Areas: GIAPREZA® (septic shock): Identified as a major growth driver due to high unmet medical need. XACDURO® (bacterial pneumonia): Showing strong commercial momentum and international adoption, particularly in China. ZEVTERA® (MRSA/ bloodstream infections): Expected to launch in the U.S. in mid-2025, offering significant potential in the antimicrobial market. NUZOLVENCE (gonorrhea): FDA-approved in 2026, targeting a high-unmet-need infectious disease area.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 2:37 AM
$INVA Share Price: $23.30 Contract Selected: Sep 18, 2026 $22.5 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.41 – $4.16 Potential Upside: 51% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
kiwitc2000
kiwitc2000 Mar. 31 at 12:19 PM
$INVA Above 23.50
0 · Reply
NorthStarStats
NorthStarStats Mar. 31 at 9:53 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $INVA Score 100, $INSM Score 98, $BMY Score 97, $COST Score 82, $NWSA Score 70
0 · Reply
Kookoovia
Kookoovia Mar. 23 at 8:58 PM
$GURE $INVA $LMFA $SEGG Its a dude
0 · Reply
ChartChartist
ChartChartist Mar. 22 at 9:27 PM
$GURE damn girl ur so fine. Ever since the DNA test showed my fiancé and I were too genetically close of first cousins I’ve been lonely. $INVA .29 cheapies $LMFA double bottoms $SEGG lets gooo GURE me on Monday. Top play idea. Oil. Nano float
0 · Reply
Doozio
Doozio Mar. 19 at 11:21 PM
$INVA 🐒🍌🧠⏰♾️
0 · Reply
Latest News on INVA
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Mar 10, 2026, 6:30 AM EDT - 6 weeks ago

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Feb 25, 2026, 4:05 PM EST - 2 months ago

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 8:00 AM EST - 2 months ago

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Dec 12, 2025, 4:56 PM EST - 4 months ago

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Dec 12, 2025, 1:33 PM EST - 4 months ago

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Dec 11, 2025, 6:35 PM EST - 4 months ago

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 5 months ago

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Nov 5, 2025, 4:05 PM EST - 6 months ago

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct 21, 2025, 8:00 AM EDT - 6 months ago

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Oct 20, 2025, 8:00 AM EDT - 6 months ago

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Innoviva to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 8 months ago

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Aug 13, 2025, 8:00 AM EDT - 9 months ago

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Jun 12, 2025, 7:00 AM EDT - 11 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Jun 10, 2025, 6:00 AM EDT - 11 months ago

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

May 20, 2025, 6:00 AM EDT - 1 year ago

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

May 20, 2025, 1:15 AM EDT - 1 year ago

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

May 7, 2025, 4:05 PM EDT - 1 year ago

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Mar 12, 2025, 5:08 PM EDT - 1 year ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

ARMP

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Feb 26, 2025, 4:04 PM EST - 1 year ago

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Dec 16, 2024, 7:00 AM EST - 1 year ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Dec 16, 2024, 1:15 AM EST - 1 year ago

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva to Participate in the UBS Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Nov 6, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Jun 18, 2024, 1:44 PM EDT - 2 years ago

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

GSK

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 8, 2024, 4:05 PM EDT - 2 years ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the BofA Securities Health Care Conference

May 8, 2024, 7:00 AM EDT - 2 years ago

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Apr 24, 2024, 7:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Feb 29, 2024, 4:05 PM EST - 2 years ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

10 stocks you can bet on being inflation-proof

Feb 28, 2024, 2:48 PM EST - 2 years ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 1, 2023, 4:15 PM EDT - 2 years ago

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Innoviva to Participate in the Cantor Global Healthcare Conference

Sep 19, 2023, 8:30 AM EDT - 2 years ago

Innoviva to Participate in the Cantor Global Healthcare Conference

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Sep 18, 2023, 8:00 AM EDT - 2 years ago

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 25, 2023, 4:52 PM EDT - 2 years ago

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 2, 2023, 4:05 PM EDT - 2 years ago

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Jul 11, 2023, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Jun 6, 2023, 4:05 PM EDT - 3 years ago

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 10:32 PM EDT - 3 years ago

FDA approves Innoviva's bacterial pneumonia treatment

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

May 23, 2023, 6:42 PM EDT - 3 years ago

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

All4Retiring
All4Retiring Apr. 20 at 11:21 PM
$INVA $ARMP Innoviva (through its subsidiary Innoviva Strategic Opportunities LLC) beneficially owns approximately 55.47 million shares of Armata Pharmaceuticals (ARMP) on a fully diluted/as-converted and as-exercised basis, representing about 83.1–83.3% of Armata’s common stock. http://stocktitan.net This includes: • Direct/common shares owned: 25,076,769 shares (roughly 68–69% of currently outstanding shares). http://wallstreetzen.com • Additional shares from warrants (about 10.65 million) and a convertible loan (about 19.74 million shares upon conversion, excluding accrued interest). http://sec.gov Armata has approximately 36.2–36.6 million shares outstanding as of early 2026 (e.g., ~36.23 million in recent reports and ~36.6 million as of March 2026). http://finance.yahoo.com This ownership stems from multiple investments since 2020 (initial ~$25M deal, followed by $45M in 2022, and later credit facilities/loans that are partially convertible), with Innoviva as Armata’s largest/majority shareholder
0 · Reply
wizeinvesting
wizeinvesting Apr. 16 at 8:30 AM
$INVA $CCJ $NBR $WEN While most investors remain focused on large-cap leaders and headline-driven trades, a quieter shift is unfolding beneath the surface. Small-cap stocks—long overlooked due to higher rates and macro uncertainty—are beginning to present selective opportunities where price no longer reflects underlying business performance. The key isn’t simply that these stocks are cheap, but that some are still executing, generating earnings, and adapting despite negative sentiment. From a profitable biotech with royalty-backed income, to an energy services firm leveraged to global demand, to a consumer brand priced for decline, the real opportunity lies in identifying where pessimism has gone too far. In the final section, we break down why the biggest edge in this market isn’t finding the cheapest stocks—but understanding which discounted companies are still fundamentally intact, and how that distinction can define... https://www.wizeinvesting.com/p/how-ccj-delivered-607-gains-in-5-years
0 · Reply
Doozio
Doozio Apr. 14 at 12:37 AM
$INVA it’s about to get obvious ONTO 🐒🍌🧠⏰♾️?
0 · Reply
stubbybrown
stubbybrown Apr. 10 at 2:37 AM
$INVA Innoviva, Inc. has the greatest future revenue growth potential in the Innoviva Specialty Therapeutics (IST) segment, specifically within hospital-based critical care and infectious disease treatments. The IST division is experiencing rapid growth, with net product sales rising by 77% in 2025 to $172.1 million and projected to exceed $150 million in U.S. sales in 2026. Key Products in High-Need Areas: GIAPREZA® (septic shock): Identified as a major growth driver due to high unmet medical need. XACDURO® (bacterial pneumonia): Showing strong commercial momentum and international adoption, particularly in China. ZEVTERA® (MRSA/ bloodstream infections): Expected to launch in the U.S. in mid-2025, offering significant potential in the antimicrobial market. NUZOLVENCE (gonorrhea): FDA-approved in 2026, targeting a high-unmet-need infectious disease area.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 2:37 AM
$INVA Share Price: $23.30 Contract Selected: Sep 18, 2026 $22.5 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.41 – $4.16 Potential Upside: 51% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
kiwitc2000
kiwitc2000 Mar. 31 at 12:19 PM
$INVA Above 23.50
0 · Reply
NorthStarStats
NorthStarStats Mar. 31 at 9:53 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $INVA Score 100, $INSM Score 98, $BMY Score 97, $COST Score 82, $NWSA Score 70
0 · Reply
Kookoovia
Kookoovia Mar. 23 at 8:58 PM
$GURE $INVA $LMFA $SEGG Its a dude
0 · Reply
ChartChartist
ChartChartist Mar. 22 at 9:27 PM
$GURE damn girl ur so fine. Ever since the DNA test showed my fiancé and I were too genetically close of first cousins I’ve been lonely. $INVA .29 cheapies $LMFA double bottoms $SEGG lets gooo GURE me on Monday. Top play idea. Oil. Nano float
0 · Reply
Doozio
Doozio Mar. 19 at 11:21 PM
$INVA 🐒🍌🧠⏰♾️
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 7:00 PM
$INVA Q4 '25 Earnings Results & Recap Innoviva reported total revenue of $411.3M for FY2025, with net product sales increasing 77% to $172.1M. Net income for Innoviva was $271.2M ($4.02 basic EPS).
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 1:31 PM
$INVA RSI: 61.95, MACD: 0.7736 Vol: 1.00, MA20: 22.64, MA50: 20.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheBehavioralTrader
TheBehavioralTrader Feb. 26 at 7:57 PM
$INVA looks like normal profit taking to me I expect this to move back to 52-week highs.
0 · Reply
All4Retiring
All4Retiring Feb. 26 at 5:05 PM
$INVA Link to Oppenheimer Fireside Chat today w CEO https://investor.inva.com/presentations-events
0 · Reply
All4Retiring
All4Retiring Feb. 26 at 1:33 PM
$INVA https://www.stocktwits.com/symbol/INVA/companycall
0 · Reply
All4Retiring
All4Retiring Feb. 25 at 10:59 PM
Investor Relations - Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress - Innoviva $INVA https://investor.inva.com/news-releases/news-release-details/innoviva-reports-fourth-quarter-and-full-year-2025-financial
0 · Reply
Itinerant
Itinerant Feb. 25 at 9:41 PM
$INVA This is a beautiful earnings report, thanks, in part to Armata.
1 · Reply
robber
robber Feb. 25 at 9:05 PM
$INVA what ever happened to this selling with its royalties at one point? Anyone have any info?
0 · Reply
Rickycello
Rickycello Feb. 25 at 12:31 PM
$INVA bear: $18 base: $33 bull: $46 Intrinsic value: $26.72 Sell price target: $32.6 (28% margin) Reward / risk: 8.66 Risk / reward: 0.12
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 1:03 PM
$INVA Current Stock Price: $23.39 Contracts to trade: $22.5 INVA Mar 20 2026 Call Entry: $1.15 Exit: $1.50 ROI: 31% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Itinerant
Itinerant Feb. 21 at 5:39 PM
$INVA I believe that INVA is under valued because historically the company has shown weak earnings growth, and the company's strong balance sheet is ignored by the market (a common cause of mis-valuation). Now, however, the market is expecting a strengthening in operating cash flow resulting from the newly approved drug. I expect this stock price trend to continue, unless the earnings expectations disappoint. The management of this company is very careful and conservative. You may recall that this company spun out Theravance BioPharma, which is an equally excellent company. I am long.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 18 at 3:10 AM
Commercial-stage bios trading near 4.5 highs since 10/1/2025. All 5 below trading at 4.5 month highs $GERN has been trading between $1.25 & $1.45 since April 2025, and after JPM. If anyone is aware why GERN is running please share. $TWST is way up consistently since 2/2/26 after big guidance for FY2026. $PGEN Consensus for Papzimeos as new first-line SOC for Papillomatosis per 1/20/26 PR $INVA There is no PR nor SEC filing since 12/25 outside of Nuzolvence approval $KNSA $900MM in FY26 product revenue guidance from $677 in FY25 (approval in 3/2021). Still trading at 4.0X FY2026 For entertainment purposes only.
1 · Reply